Please login to the form below

Not currently logged in

BMS' Opdivo backed as melanoma therapy in EU

First checkpoint inhibitor to be recommended for approval in the region

Bristol-Myers Squibb (BMS) buildingBristol-Myers Squibb's Opdivo has become the first checkpoint inhibitor to be recommended for approval in the EU, grabbing a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) as a treatment for melanoma.

The EMA's advisory committee recommended BMS' PD-1 inhibitor for use as a first- and second-line therapy for patients with advanced (unresectable or metastatic) melanoma after an accelerated assessment.

The opinion is based on two phase III studies, one in treatment-naïve patients in which it was compared to the standard chemotherapy dacarbazine and the other in previously-treated patients, with Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone.

Opdivo was approved as a second-line treatment for melanoma in the US last December after being granted a broader license in Japan earlier in the year, and bagged a second FDA approval as a second-line non-small cell lung cancer (NSCLC) therapy - a much larger market opportunity - in March.

The CHMP opinion is another boost for BMS as it goes head-to-head in the checkpoint inhibitor market with rival Merck & Co, whose Keytruda (pembrolizumab) product is also approved for second-line melanoma therapy in the US and was recently filed for approval in NSCLC.

Neither BMS nor Merck has yet reported first-quarter results, which should give a first indication of how their respective drugs are faring the marketplace. Both companies are due to report their financials tomorrow.

Other CHMP opinions

Opdivo was one of 11 new medicine recommended for approval by the CHMP at its meeting last week.

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -  along with Daiichi Sankyo's novel oral anticoagulant (NOAC) Lixiana (edoxaban), which has been available in Japan for some but got the green light from the FDA under the Savaysa brand name in January. 

Other drugs receiving positive opinions included IDB's radiopharmaceutical precursor LuMark (lutetium -177 chloride) for radiolabelling carrier molecules, along with several generic drugs. However, there was disappointment for Biovest Europe after its non-Hodgkin's lymphoma therapy Lympreva (dasiprotimut-t) was turned down by the CHMP.

The panel said the way Lympreva's main supportive study was designed and carried out was inadequate to allow it to establish the medicine's benefit, and it also had concerns about some aspects of its manufacture and quality control.

Safety issue with new HCV drugs

The CHMP also said it had confirmed a risk of severe bradycardia or heart block when Gilead's hepatitis C drug Harvoni (sofosbuvir with ledipasvir) - or a combination of Sovaldi (sofosbuvir) and BMS' Daklinza (daclatasvir) - are used in patients who are also taking the antiarrhythmic drug amiodarone.

In patients taking these medicines, amiodarone should only be used if other anti-arrhythmics cannot be given, it recommends.

Article by
Phil Taylor

27th April 2015

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....